Catalent, Inc. CTLT was a big mover last session, as the company saw its shares rise almost 10% on the day. The upside was driven by the company’s improved third-quarter fiscal 2017 results. Also, this led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 12% in the past one-month time frame.
The company has seen one positive estimate revisions in the past 30 days. Also, its Zacks Consensus Estimate moved higher over the same timeframe. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Catalent currently holds a Zacks Rank #2 (Buy).
Catalent, Inc. Price
Catalent, Inc. Price | Catalent, Inc. Quote
A top-ranked stock in the Medical – Drugs industry is Infinity Pharmaceuticals, Inc. INFI sporting a Zacks Rank #1 (Strong Buy). You can the complete list of today’s Zacks #1 Rank stocks here.
Is CTLT going up? Or down? Predict to see what others think: Up or Down
The Best & Worst of Zacks
Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. From 1988 through 2015 this list has averaged a stellar gain of +25% per year. Plus, you may download 220 Zacks Rank #5 "Strong Sells." Even though this list holds many stocks that seem to be solid, it has historically performed 6X worse than the market. See these critical buys and sells free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Catalent, Inc. (CTLT): Free Stock Analysis Report
Infinity Pharmaceuticals, Inc. (INFI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research